After patient deaths, failed partnerships and a stock scandal, Hanmi finally gives up on controversial olmutinib. What did we learn?
The olmutinib development program is finally dead.
South Korea’s Hanmi has determined that the drug — once partnered with Boehringer Ingelheim and Zai Lab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
